OAT Agrio Co., Ltd.
4979・Standard Market・Chemicals
Governance
Company with an Audit and Supervisory Committee. The Board of Directors consists of 9 members (including 3 outside directors, all of whom are Audit and Supervisory Committee members and independent officers), with an outside director ratio of 33.3%. A voluntary Nomination and Compensation Committee has been established, with outside directors comprising a majority of its members. In FY2025, the Board of Directors met 14 times, with an attendance rate of 100% for all members.
Risk Management
The Company has established a Risk Management Committee, chaired by the President and Representative Director, which identifies potential risks, develops internal regulations, and provides employee training. The Sustainability Promotion Committee identifies and assesses company-wide risks—including climate-related risks—at least once a year, with a system in place to report to the Board of Directors. A Compliance Committee, an Internal Control Promotion Committee, and internal and external hotlines have also been established.
Shareholder Returns
Basic policy is stable dividends, with dividends paid twice a year (interim and year-end). For FY2025 (ending December 2025), the dividend is ¥60 per share (¥30 interim, ¥30 year-end). For FY2026 (ending December 2026), the same amount of ¥60 per share (¥30 interim, ¥30 year-end) is forecast. No change to the dividend forecast. No mention of share buybacks.
Dividend Policy
The policy is to pay stable dividends while taking into consideration the strengthening of the financial structure and the accumulation of internal reserves. In principle, dividends are paid twice a year, as an interim dividend and a year-end dividend. Actual results for FY2025 (ending December 2025) were ¥60 per share (¥30 interim, ¥30 year-end). The forecast for FY2026 (ending December 2026) is also ¥60 per share (¥30 interim, ¥30 year-end), unchanged from the most recently announced dividend forecast.
ESG
Based on the TCFD framework, the company conducted 2°C and 4°C scenario analyses to identify transition and physical risks and opportunities. It has set a target of net-zero greenhouse gas emissions by 2050; for FY2025 (ending December 2025), Scope 1 emissions were 1,000 tCO2eq and Scope 2 emissions were 1,725 tCO2eq (both reduced year on year). On the human capital front, the company has set a target of 20% for the ratio of female managers (currently 9.6%), has been certified as a 2025 Excellent Health Management Corporation, and is promoting business reform through DX and AI utilization. The company positions the expansion of green products and biostimulant products as a climate change opportunity, and has published its Sustainability Report 2026.
Last updated: March 24, 2026